Biology subjects

Mirbaha, H.

Publications and source records attributed to Mirbaha, H..

4 recordsLinked to original sources

bioRxiv2022

Seed-competent tau monomer initiates pathology in PS19 tauopathy mice

Tau aggregation into ordered assemblies causes myriad neurodegenerative tauopathies. We previously reported that tau monomer exists in either inert (Mi) or seed-competent (Ms) conformational ensembles, and that Ms encodes strains, which are biologically active, self-propagating assemblies. We have previously isolated Ms from tauopathy brains, but it is unknown if disease begins with Ms formation followed by fibril assembly, or if Ms derives from fibrils and is an epiphenomenon. Consequently, we studied a tauopathy mouse model (PS19) that expresses full-length human (1N4R) tau containing a disease-associated mutation (P301S). Using tau repeat domain biosensor cells, we detected insoluble tau seeding activity at 2 months. We found insoluble tau protein assemblies by immunoblot at 3 months. We next immunopurified monomer from mice aged 1-6 weeks using size exclusion chromatography. We detected soluble seeding activity at 4 weeks, before insoluble material or larger assemblies, with assemblies ranging from n=1-3 tau units. By 5 and 6 weeks, large soluble assemblies had formed. This indicated the first detectable pathological forms of tau were Ms. We next tested for post-translational modifications of tau monomer from 1-6 weeks. We detected no phosphorylation unique to Ms in PS19 or Alzheimers disease brain. We conclude that tauopathy begins with formation of Ms monomer, whose activity is phosphorylation-independent. Ms self-assembles to form oligomers before it forms insoluble fibrils. The conversion of tau monomer from Mi to Ms thus constitutes the first detectable step in the initiation of tauopathy in this mouse model, with obvious implications for origins of disease in humans.

neuroscience↗

bioRxiv2020

DnaJC7 binds natively folded structural elements in tau to inhibit amyloid formation

Molecular chaperones, including Hsp70/Hsp40 families, play central roles in binding substrates to prevent their aggregation. How Hsp40s select different conformations of substrates remains poorly understood. Here, we report a novel interaction between the Hsp40 DnaJC7 and tau that efficiently suppresses tau aggregation in vitro and in cells. DnaJC7 binds preferentially to natively folded wild-type tau, but disease-associated mutants in tau reduce chaperone binding affinity. We identify that DnaJC7 uses a single TPR domain to recognize a {beta}-turn element in tau that contains the 275VQIINK280 amyloid motif. Wild-type tau {beta}-turn fragments, but not mutant fragments, can block full-length tau binding to DnaJC7. These data suggest DnaJC7 preferentially binds and stabilizes natively folded conformations of tau to prevent tau conversion into amyloids. This identifies a novel mechanism of tau aggregation regulation that can be exploited as both a diagnostic and a therapeutic intervention.

biophysics↗

bioRxiv2019

Site-specific hyperphosphorylation of tau inhibits its fibrillization in vitro, blocks its seeding capacity in cells, and disrupts its microtubule binding; Implications for the native state stabilization of tau

The consistent observation of aggregated phosopho-tau in the pathology of Alzheimers disease and other tauopathies has contributed to the emergence of a model where hyperphosphorylation of tau causes its disassociation from microtubules and subsequent pathological polymerization. However, the large number of possible phosphorylation sites in tau and lack of robust methods that enable the preparation of homogeneously phosphorylated tau species have made it difficult to validate this model. Herein, we applied a total chemical synthetic approach to site-specifically phosphorylate single (pS356) or multiple (pS356/pS262 and pS356/pS262/pS258) residues within the microtubule binding repeat domain (MTBD) of tau and show that hyperphosphorylation within the microtubule MTBD inhibits K18 tau 1) aggregation in vitro; 2) its seeding activity in cells, and 3) its ability to promote microtubule polymerization. The inhibition increased with the number of phosphorylated sites, with phosphorylation at S262 having the strongest effect. On the basis of these findings, we propose that targeting the kinases that regulate phosphorylation at these sites could provide a viable strategy to stabilize the native state of tau and inhibit its aggregation. Taken together, our results argue against the pathogenic hyperphosphorylation hypothesis and underscore the critical importance of revisiting the role of site-specific hyperphosphorylation of tau in regulating its function in health and disease.\n\nO_FIG O_LINKSMALLFIG WIDTH=159 HEIGHT=200 SRC=\"FIGDIR/small/772046v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (48K):\norg.highwire.dtl.DTLVardef@1328421org.highwire.dtl.DTLVardef@1809f73org.highwire.dtl.DTLVardef@16459a4org.highwire.dtl.DTLVardef@1393751_HPS_FORMAT_FIGEXP M_FIG Table of content C_FIG

neuroscience↗

bioRxiv2017

Inert and seed-competent tau monomers elucidate the structural origins of aggregation

Tauopathies feature progressive accumulation of tau amyloids. Pathology may begin when these amplify from a protein template, or seed, whose structure is unknown. We have purified and characterized distinct forms of tau monomer--inert (Mi) and seed-competent (Ms). Recombinant Ms triggered intracellular tau aggregation, induced tau fibrillization in vitro, and self-assembled. Ms from Alzheimers disease also seeded aggregation and self-assembled in vitro to form seed-competent multimers. We used crosslinking with mass spectrometry to probe structural differences in Mi vs. Ms. Crosslinks informed models of local peptide structure within the repeat domain which suggest relative inaccessibility of residues that drive aggregation (VQIINK/VQIVYK) in Mi, and exposure in Ms. Limited proteolysis supported this idea. Although tau monomer has been considered to be natively unstructured, our findings belie this assumption and suggest that initiation of pathological aggregation could begin with conversion of tau monomer from an inert to a seed-competent form.

neuroscience↗